Zkusit zdarma
Incyte Corporation

Incyte Corporation

INCY
Cena:
$ 97.10
-0.06 (-0.06%)
Valuace
83
Růst
93
Zdraví
40
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Here's Why Incyte (INCY) is a Strong Momentum Stock

Here's Why Incyte (INCY) is a Strong Momentum Stock

10:51 26-05-2026

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the ...

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

9:00 26-05-2026

Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global He...

Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out

Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out

12:02 25-05-2026

Incyte NASDAQ: INCY Chief Medical Officer Steven Stein outlined the company's development priorities...

Here's Why Incyte (INCY) is a Strong Value Stock

Here's Why Incyte (INCY) is a Strong Value Stock

10:41 22-05-2026

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t...

Why Incyte (INCY) is a Top Growth Stock for the Long-Term

Why Incyte (INCY) is a Top Growth Stock for the Long-Term

10:46 21-05-2026

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi...

Inside Incyte's $120 Million AI For Drug Development Deal

Inside Incyte's $120 Million AI For Drug Development Deal

12:10 20-05-2026

In this week's edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep ...

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

9:00 20-05-2026

[url="]Incyte[/url] (Nasdaq:INCY) and [url="]Genesis Molecular AI[/url] today announced a significan...

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

8:00 20-05-2026

WILMINGTON, Del. & SAN MATEO, Calif.--(BUSINESS WIRE)--Incyte and Genesis expand molecular AI collab...

Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

13:40 19-05-2026

Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcri...

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

8:00 19-05-2026

WILMINGTON, Del. & SAN FRANCISCO--(BUSINESS WIRE)---- $INCY--Incyte and Edison Scientific Announce S...

Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

1:10 18-05-2026

Incyte NASDAQ: INCY President and CEO Bill Meury said the company's post-Jakafi growth profile has b...

Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

19:20 13-05-2026

Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Rem...

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

9:30 12-05-2026

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--Incyte Announces More Than 20 Abstracts Accept...

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

8:50 07-05-2026

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced final 24-week data from the ...

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16:30 06-05-2026

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing R...

Why Incyte (INCY) is a Top Value Stock for the Long-Term

Why Incyte (INCY) is a Top Value Stock for the Long-Term

10:41 06-05-2026

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the ...

Here's Why Incyte (INCY) is a Strong Growth Stock

Here's Why Incyte (INCY) is a Strong Growth Stock

10:45 05-05-2026

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi...

Why Incyte (INCY) is a Top Momentum Stock for the Long-Term

Why Incyte (INCY) is a Top Momentum Stock for the Long-Term

10:51 04-05-2026

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t...

New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]

New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]

12:00 03-05-2026

/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics is pleased to announc...

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

17:28 01-05-2026

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug ...

close

INCYTE REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

10-02-2026
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY--INCYTE REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANC...
Více zde

INCYTE ANNOUNCES POSITIVE CHMP OPINION FOR ZYNYZ® (RETIFANLIMAB) FOR FIRST-LINE TREATMENT OF ADVANCED SQUAMOUS CELL CARCINOMA OF THE ANAL CANAL (SCAC)

30-01-2026
MORGES, SWITZERLAND--(BUSINESS WIRE)---- $INCY--POSITIVE CHMP OPINION FOR ZYNYZ® (RETIFANLIMAB) FOR...
Více zde

INCYTE TO REPORT FOURTH QUARTER AND YEAR-END 2025 FINANCIAL RESULTS

27-01-2026
WILMINGTON, DEL.--(BUSINESS WIRE)--INCYTE (NASDAQ:INCY) ANNOUNCED TODAY THAT IT HAS SCHEDULED ITS FO...
Více zde

INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF TAFASITAMAB (MONJUVI®/MINJUVI®) AS A FIRST-LINE TREATMENT FOR DIFFUSE LARGE B-CELL LYMPHOMA

05-01-2026
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY--INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL ...
Více zde

INCYTE JAPAN ANNOUNCES APPROVAL OF MINJUVI® (TAFASITAMAB) IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

22-12-2025
TOKYO--(BUSINESS WIRE)---- $INCY--INCYTE JAPAN ANNOUNCES APPROVAL OF MINJUVI® (TAFASITAMAB) IN COMB...
Více zde

INCYTE JAPAN ANNOUNCES APPROVAL OF ZYNYZ® (RETIFANLIMAB) FOR THE FIRST-LINE TREATMENT OF ADVANCED ANAL CANCER

22-12-2025
TOKYO--(BUSINESS WIRE)---- $INCY--INCYTE JAPAN ANNOUNCES APPROVAL OF ZYNYZ® (RETIFANLIMAB) FOR THE ...
Více zde

INCYTE TO PRESENT AT UPCOMING INVESTOR CONFERENCE

18-12-2025
WILMINGTON, DEL.--(BUSINESS WIRE)--INCYTE (NASDAQ:INCY) ANNOUNCED TODAY THAT IT WILL PRESENT AT THE ...
Více zde

INCYTE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF MINJUVI® (TAFASITAMAB) FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

17-12-2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY--INCYTE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF MINJUV...
Více zde

INCYTE ANNOUNCES CHANGE TO ITS BOARD OF DIRECTORS

12-12-2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY--INCYTE ANNOUNCES CHANGE TO ITS BOARD OF DIRECTORS....
Více zde

INCYTE PRESENTS UPDATED POSITIVE DATA AT ASH 2025 REINFORCING THE POTENTIAL OF INCA033989, ITS FIRST-IN-CLASS MUTCALR-TARGETED MONOCLONAL ANTIBODY, IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

08-12-2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY #ASH2025--UPDATED POSITIVE DATA AT ASH 2025 REINFORCE TH...
Více zde

INCYTE'S FIRST-IN-CLASS MUTCALR-TARGETED MONOCLONAL ANTIBODY, INCA033989, GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA

07-12-2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY #ASH2025--INCYTE'S FIRST-IN-CLASS MUTCALR-TARGETED MONOC...
Více zde

INCYTE REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

03-12-2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY--INCYTE REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RU...
Více zde

GLOBAL VITILIGO FOUNDATION APPLAUDS PARTNERSHIP BETWEEN INCYTE AND WINNIE HARLOW TO ELEVATE AWARENESS AND UNDERSTANDING OF VITILIGO

03-12-2025
MECHANICSBURG, PA.--(BUSINESS WIRE)--THE GLOBAL VITILIGO FOUNDATION (GVF) COMMENDS THE NEWLY ANNOUNC...
Více zde

INCYTE AND WINNIE HARLOW JOIN FORCES TO SHARE HER PERSONAL VITILIGO STORY AND SPARK CONVERSATION AND UNDERSTANDING

02-12-2025
WILMINGTON, DEL.--(BUSINESS WIRE)--INCYTE AND WINNIE HARLOW JOIN FORCES TO SHARE HER PERSONAL VITILI...
Více zde

INCYTE APPOINTS RICHARD HOFFMAN AS EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL

01-12-2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY--INCYTE APPOINTS RICHARD HOFFMAN AS EXECUTIVE VICE PRESI...
Více zde

INCYTE TO PRESENT AT UPCOMING INVESTOR CONFERENCES

19-11-2025
WILMINGTON, DEL.--(BUSINESS WIRE)--INCYTE (NASDAQ:INCY) ANNOUNCED TODAY THAT IT WILL PRESENT AT THE ...
Více zde

INCYTE ANNOUNCES POSITIVE CHMP OPINION FOR MINJUVI® (TAFASITAMAB) FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)

17-11-2025
MORGES, SWITZERLAND--(BUSINESS WIRE)---- $INCY--INCYTE ANNOUNCES POSITIVE CHMP OPINION FOR MINJUVI®...
Více zde

INCYTE'S MOMENTS OF CLARITY PROGRAM EXPANDS TO HIGHLIGHT POWERFUL PATIENT STORIES IN VITILIGO AND PEDIATRIC ECZEMA

06-11-2025
WILMINGTON, DEL.--(BUSINESS WIRE)--INCYTE'S MOMENTS OF CLARITY PROGRAM EXPANDS TO HIGHLIGHT POWERFUL...
Více zde

PRELUDE THERAPEUTICS ANNOUNCES EXCLUSIVE OPTION AGREEMENT WITH INCYTE TO ADVANCE MUTANT SELECTIVE JAK2V617F JH2 INHIBITORS

04-11-2025
INCYTE SECURES AN EXCLUSIVE OPTION TO ACQUIRE PRELUDE'S MUTANT SELECTIVE JAK2V617F JH2 INHIBITOR PRO...
Více zde

INCYTE ANNOUNCES MORE THAN 50 ABSTRACTS ACCEPTED FOR PRESENTATION AT THE 2025 ASH ANNUAL MEETING

03-11-2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY #ASH2025--INCYTE ANNOUNCES MORE THAN 50 ABSTRACTS ACCEPT...
Více zde

INCYTE TO PRESENT AT UPCOMING INVESTOR CONFERENCES

30-10-2025
WILMINGTON, DEL.--(BUSINESS WIRE)--INCYTE (NASDAQ:INCY) ANNOUNCED TODAY THAT IT WILL PRESENT AT THE ...
Více zde

KNIGHT THERAPEUTICS ANNOUNCES APPROVAL AND LAUNCH OF MINJUVI® (TAFASITAMAB) IN ARGENTINA

30-10-2025
MONTREAL, OCT. 30, 2025 (GLOBE NEWSWIRE) -- KNIGHT THERAPEUTICS INC., (TSX: GUD) ("KNIGHT") A PAN-AM...
Více zde

INCYTE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

28-10-2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY--INCYTE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND...
Více zde

INCYTE AND ENABLE INJECTIONS ANNOUNCE STRATEGIC PARTNERSHIP FOR ENFUSE® ON-BODY DELIVERY SYSTEM

27-10-2025
WILMINGTON, DEL. & CINCINNATI--(BUSINESS WIRE)---- $INCY--INCYTE AND ENABLE INJECTIONS ANNOUNCE STRA...
Více zde

INCYTE ANNOUNCES NEW DATA FROM PHASE 3B TRUE-AD4 TRIAL OF OPZELURA® (RUXOLITINIB CREAM) IN ADULTS WITH MODERATE ATOPIC DERMATITIS

25-10-2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY #ISAD2025--INCYTE ANNOUNCES NEW DATA FROM PHASE 3B TRUE-...
Více zde

LILLY'S BARICITINIB DELIVERED NEAR-COMPLETE SCALP HAIR REGROWTH AT ONE YEAR FOR ADOLESCENTS WITH SEVERE ALOPECIA AREATA IN PHASE 3 BRAVE-AA-PEDS TRIAL

24-10-2025
THIS TRIAL IS THE FIRST AND LARGEST STUDY SPECIFICALLY DESIGNED TO EVALUATE CHILDREN AND ADOLESCENTS...
Více zde

INCYTE ANNOUNCES PHASE 1 RESULTS FOR ITS TGFΒR2×PD-1 BISPECIFIC ANTIBODY IN ADVANCED COLORECTAL CANCER AND KRAS G12D INHIBITOR IN ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA

19-10-2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY #ESMO25--INCYTE ANNOUNCES PHASE 1 RESULTS FOR ITS TGFΒR...
Více zde

DATA FROM INCYTE'S TGFΒR2×PD-1 BISPECIFIC ANTIBODY AND KRAS G12D INHIBITOR TO BE PRESENTED AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO) CONGRESS 2025

12-10-2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY #ESMO2025--DATA FROM INCYTE'S TGFΒR2×PD-1 BISPECIFIC A...
Více zde

INCYTE TO REPORT THIRD QUARTER FINANCIAL RESULTS

08-10-2025
WILMINGTON, DEL.--(BUSINESS WIRE)--INCYTE (NASDAQ:INCY) ANNOUNCED TODAY THAT IT HAS SCHEDULED ITS TH...
Více zde

CHINA MEDICAL SYSTEM (867.HK; 8A8.SG) POSITIVE RESULTS FROM CHINA PHASE 3 CLINICAL TRIAL OF INNOVATIVE DRUG RUXOLITINIB CREAM WITH AD INDICATION

28-09-2025
SHENZHEN, CHINA, SEPT. 28, 2025 (GLOBE NEWSWIRE) -- CHINA MEDICAL SYSTEM HOLDINGS LIMITED (“CMS”...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-10 00:00:008-KStáhnout
2026-02-10 00:00:0010-KStáhnout
2025-12-12 00:00:008-KStáhnout
2025-10-28 00:00:008-KStáhnout
2025-10-28 00:00:0010-QStáhnout
2025-10-03 01:00:008-KStáhnout
2025-10-03 00:00:008-KStáhnout
2025-08-07 01:00:008-KStáhnout
2025-08-07 00:00:008-KStáhnout
2025-07-29 01:00:008-KStáhnout
2025-07-29 01:00:0010-QStáhnout
2025-07-29 00:00:008-KStáhnout
2025-07-29 00:00:0010-QStáhnout
2025-06-27 01:00:008-KStáhnout
2025-06-27 00:00:008-KStáhnout
2025-06-11 01:00:008-KStáhnout
2025-06-11 00:00:008-KStáhnout
2025-05-14 01:00:008-KStáhnout
2025-05-14 00:00:008-KStáhnout
2025-04-29 01:00:008-KStáhnout
2025-04-29 01:00:0010-QStáhnout
2025-04-29 00:00:008-KStáhnout
2025-04-29 00:00:0010-QStáhnout
2025-02-10 00:00:008-KStáhnout
2025-02-10 00:00:0010-KStáhnout
2025-02-09 23:00:008-KStáhnout
2025-02-09 23:00:0010-KStáhnout
2025-01-10 00:00:008-KStáhnout
2025-01-09 23:00:008-KStáhnout
2024-10-29 00:00:008-KStáhnout
2024-10-29 00:00:0010-QStáhnout
2024-10-28 23:00:008-KStáhnout
2024-10-28 23:00:0010-QStáhnout
2024-07-30 01:00:008-KStáhnout
2024-07-30 01:00:0010-QStáhnout
2024-07-30 00:00:008-KStáhnout
2024-07-30 00:00:0010-QStáhnout
2024-07-03 01:00:008-KStáhnout
2024-07-03 00:00:008-KStáhnout
2024-06-14 01:00:008-KStáhnout
2024-06-14 00:00:008-KStáhnout
2024-05-13 01:00:008-KStáhnout
2024-05-13 00:00:008-KStáhnout
2024-04-30 01:00:008-KStáhnout
2024-04-30 01:00:0010-QStáhnout
2024-04-30 00:00:008-KStáhnout
2024-04-30 00:00:0010-QStáhnout
2024-02-13 00:00:008-KStáhnout
2024-02-13 00:00:0010-KStáhnout
2024-02-12 23:00:008-KStáhnout
2023-10-31 00:00:008-KStáhnout
2023-10-31 00:00:0010-QStáhnout
2023-10-30 23:00:008-KStáhnout
2023-10-30 23:00:0010-QStáhnout
2023-09-12 01:00:008-KStáhnout
2023-09-12 00:00:008-KStáhnout
2023-08-01 01:00:008-KStáhnout
2023-08-01 01:00:0010-QStáhnout
2023-08-01 00:00:008-KStáhnout
2023-08-01 00:00:0010-QStáhnout
2023-06-15 01:00:008-KStáhnout
2023-06-15 00:00:008-KStáhnout
2023-05-08 01:00:008-KStáhnout
2023-05-08 00:00:008-KStáhnout
2023-05-02 01:00:008-KStáhnout
2023-05-02 01:00:0010-QStáhnout
2023-05-02 00:00:008-KStáhnout
2023-05-02 00:00:0010-QStáhnout
2023-02-07 00:00:008-KStáhnout
2023-02-07 00:00:0010-KStáhnout
2023-02-06 23:00:008-KStáhnout
2023-02-06 23:00:0010-KStáhnout
2022-11-01 00:00:008-KStáhnout
2022-11-01 00:00:0010-QStáhnout
2022-10-31 23:00:008-KStáhnout
2022-10-31 23:00:0010-QStáhnout
2022-10-04 01:00:008-KStáhnout
2022-10-04 00:00:008-KStáhnout
2022-08-02 01:00:008-KStáhnout
2022-08-02 01:00:0010-QStáhnout
2022-08-02 00:00:008-KStáhnout
2022-08-02 00:00:0010-QStáhnout
2022-06-16 01:00:008-KStáhnout
2022-06-16 00:00:008-KStáhnout
2022-05-03 01:00:008-KStáhnout
2022-05-03 01:00:0010-QStáhnout
2022-05-03 00:00:008-KStáhnout
2022-05-03 00:00:0010-QStáhnout
2022-04-21 01:00:008-KStáhnout
2022-04-21 00:00:008-KStáhnout
2022-02-08 00:00:008-KStáhnout
2022-02-08 00:00:0010-KStáhnout
2022-02-07 23:00:008-KStáhnout
2022-02-07 23:00:0010-KStáhnout
2022-01-14 00:00:008-KStáhnout
2022-01-13 23:00:008-KStáhnout
2021-11-02 00:00:008-KStáhnout
2021-11-02 00:00:0010-QStáhnout
2021-11-01 23:00:008-KStáhnout
2021-11-01 23:00:0010-QStáhnout
2021-09-28 01:00:008-KStáhnout
2021-09-28 00:00:008-KStáhnout
2021-08-20 01:00:008-KStáhnout
2021-08-20 00:00:008-KStáhnout
2021-08-03 01:00:008-KStáhnout
2021-08-03 01:00:0010-QStáhnout
2021-08-03 00:00:008-KStáhnout
2021-08-03 00:00:0010-QStáhnout
2021-05-27 01:00:008-KStáhnout
2021-05-27 00:00:008-KStáhnout
2021-05-04 01:00:008-KStáhnout
2021-05-04 01:00:0010-QStáhnout
2021-05-04 00:00:008-KStáhnout
2021-05-04 00:00:0010-QStáhnout
2021-02-19 00:00:008-KStáhnout
2021-02-18 23:00:008-KStáhnout
2021-02-09 00:00:008-KStáhnout
2021-02-09 00:00:0010-KStáhnout
2021-02-08 23:00:008-KStáhnout
2021-02-08 23:00:0010-KStáhnout
2020-11-05 00:00:008-KStáhnout
2020-11-05 00:00:0010-QStáhnout
2020-11-04 23:00:008-KStáhnout
2020-11-04 23:00:0010-QStáhnout
2020-08-04 01:00:008-KStáhnout
2020-08-04 01:00:0010-QStáhnout
2020-08-04 00:00:008-KStáhnout
2020-08-04 00:00:0010-QStáhnout
2020-05-27 01:00:008-KStáhnout
2020-05-27 00:00:008-KStáhnout
2020-05-14 01:00:008-KStáhnout
2020-05-14 00:00:008-KStáhnout
2020-05-05 01:00:008-KStáhnout
2020-05-05 01:00:0010-QStáhnout
2020-05-05 00:00:008-KStáhnout
2020-05-05 00:00:0010-QStáhnout
2020-04-20 01:00:008-KStáhnout
2020-04-20 00:00:008-KStáhnout
2020-03-26 00:00:008-KStáhnout
2020-03-25 23:00:008-KStáhnout
2020-02-13 00:00:008-KStáhnout
2020-02-13 00:00:0010-KStáhnout
2020-02-12 23:00:008-KStáhnout
2020-02-12 23:00:0010-KStáhnout
2020-01-16 00:00:008-KStáhnout
2020-01-15 23:00:008-KStáhnout
2019-12-19 00:00:008-KStáhnout
2019-12-18 23:00:008-KStáhnout
2019-10-29 00:00:008-KStáhnout
2019-10-29 00:00:0010-QStáhnout
2019-10-28 23:00:008-KStáhnout
2019-10-28 23:00:0010-QStáhnout
2019-07-30 01:00:008-KStáhnout
2019-07-30 01:00:0010-QStáhnout
2019-07-30 00:00:008-KStáhnout
2019-07-30 00:00:0010-QStáhnout
2019-04-30 01:00:008-KStáhnout
2019-04-30 01:00:0010-QStáhnout
2019-04-30 00:00:008-KStáhnout
2019-04-30 00:00:0010-QStáhnout
2019-02-14 00:00:008-KStáhnout
2019-02-14 00:00:0010-KStáhnout
2019-02-13 23:00:008-KStáhnout
2019-02-13 23:00:0010-KStáhnout
2019-01-03 00:00:008-KStáhnout
2019-01-02 23:00:008-KStáhnout
2018-11-27 00:00:008-KStáhnout
2018-11-26 23:00:008-KStáhnout
2018-10-30 00:00:008-KStáhnout
2018-10-30 00:00:0010-QStáhnout
2018-10-29 23:00:008-KStáhnout
2018-10-29 23:00:0010-QStáhnout
2018-09-06 01:00:008-KStáhnout
2018-09-06 00:00:008-KStáhnout
2018-07-31 01:00:008-KStáhnout
2018-07-31 01:00:0010-QStáhnout
2018-07-31 00:00:008-KStáhnout
2018-07-31 00:00:0010-QStáhnout
2018-05-02 01:00:008-KStáhnout
2018-05-02 00:00:008-KStáhnout
2018-05-01 01:00:008-KStáhnout
2018-05-01 01:00:0010-QStáhnout
2018-05-01 00:00:008-KStáhnout
2018-05-01 00:00:0010-QStáhnout
2018-04-06 01:00:008-KStáhnout
2018-04-06 00:00:008-KStáhnout
2018-02-15 00:00:008-KStáhnout
2018-02-15 00:00:0010-KStáhnout
2018-02-14 23:00:008-KStáhnout
2018-02-14 23:00:0010-KStáhnout
2017-11-17 00:00:008-KStáhnout
2017-11-16 23:00:008-KStáhnout
2017-10-31 00:00:008-KStáhnout
2017-10-31 00:00:0010-QStáhnout
2017-10-30 23:00:008-KStáhnout
2017-10-30 23:00:0010-QStáhnout
2017-10-30 00:00:008-KStáhnout
2017-10-29 23:00:008-KStáhnout
2017-10-27 01:00:008-KStáhnout
2017-10-27 00:00:008-KStáhnout
2017-09-12 01:00:008-KStáhnout
2017-09-12 00:00:008-KStáhnout
2017-08-01 01:00:008-KStáhnout
2017-08-01 01:00:0010-QStáhnout
2017-08-01 00:00:008-KStáhnout
2017-08-01 00:00:0010-QStáhnout
2017-05-30 01:00:008-KStáhnout
2017-05-30 00:00:008-KStáhnout
2017-05-04 01:00:008-KStáhnout
2017-05-04 01:00:0010-QStáhnout
2017-05-04 00:00:008-KStáhnout
2017-05-04 00:00:0010-QStáhnout
2017-04-17 01:00:008-KStáhnout
2017-04-17 00:00:008-KStáhnout
2017-02-21 00:00:008-KStáhnout
2017-02-20 23:00:008-KStáhnout
2017-02-14 00:00:008-KStáhnout
2017-02-14 00:00:0010-KStáhnout
2017-02-13 23:00:008-KStáhnout
2017-02-13 23:00:0010-KStáhnout
2017-01-23 00:00:008-KStáhnout
2017-01-22 23:00:008-KStáhnout
2016-12-21 00:00:008-KStáhnout
2016-12-20 23:00:008-KStáhnout
2016-12-16 00:00:008-KStáhnout
2016-12-15 23:00:008-KStáhnout
2016-11-01 00:00:008-KStáhnout
2016-11-01 00:00:0010-QStáhnout
2016-10-31 23:00:008-KStáhnout
2016-08-09 01:00:008-KStáhnout
2016-08-09 00:00:008-KStáhnout
2016-07-19 00:00:008-KStáhnout
2016-06-01 00:00:008-KStáhnout
2016-05-27 00:00:008-KStáhnout
2016-05-09 00:00:008-KStáhnout
2016-04-18 00:00:008-KStáhnout
2016-04-06 00:00:008-KStáhnout
2016-02-28 23:00:008-KStáhnout
2016-02-11 23:00:0010-KStáhnout
2016-02-10 23:00:008-KStáhnout
2016-01-25 23:00:008-KStáhnout
preloader